Alpha Tau Medical (NASDAQ:DRTS) Sees Strong Trading Volume - Here's What Happened

Key Points

• Trading: 218,706 shares changed hands on Friday (down 36% from 340,510 the prior session); the stock last traded at $8.6650, up from the previous close of $8.34.
• Analyst view: MarketBeat shows a consensus rating of Hold with a consensus target of $8.67; analysts are split (2 Buy, 2 Hold, 1 Sell) and price targets range roughly $5 to $12.
• Fundamentals and pipeline: Alpha Tau has a market cap of about $722M, a negative P/E and expected full‑year EPS of -0.5, strong liquidity (current and quick ratios ~7.45), and is developing the targeted alpha‑radiation therapy DaRT, currently in clinical studies for solid tumors.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) shares saw an uptick in trading volume on Friday . 218,706 shares were traded during mid-day trading, a decline of 36% from the previous session's volume of 340,510 shares.The stock last traded at $8.6650 and had previously closed at $8.34.

Analysts Set New Price Targets

Several brokerages have recently commented on DRTS. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Zacks Research upgraded Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. Citigroup raised their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Finally, Piper Sandler restated a "neutral" rating and issued a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $8.67.

Alpha Tau Medical Price Performance

The firm has a market cap of $722.24 million, a price-to-earnings ratio of -16.06 and a beta of 1.04. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The business has a 50 day simple moving average of $7.36 and a 200-day simple moving average of $5.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Equities research analysts expect that Alpha Tau Medical Ltd. will post -0.5 earnings per share for the current year.

Hedge Funds Weigh In On Alpha Tau Medical

Hedge funds have recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC acquired a new position in Alpha Tau Medical during the 4th quarter valued at about $48,000. Envestnet Asset Management Inc. acquired a new position in Alpha Tau Medical during the 3rd quarter valued at about $62,000. Bank of America Corp DE boosted its stake in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Alpha Tau Medical during the 3rd quarter valued at about $170,000. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.